9/13
08:09 am
ostx
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
Low
Report
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
9/11
08:15 am
ostx
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
High
Report
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
9/5
10:25 am
ostx
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
9/5
08:22 am
ostx
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
Low
Report
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
8/29
07:53 am
ostx
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
Low
Report
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
8/24
05:57 am
ostx
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
8/22
08:00 am
ostx
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
Low
Report
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
8/22
06:00 am
ostx
OS Therapies Clarifies CUSIP of Common Stock
Low
Report
OS Therapies Clarifies CUSIP of Common Stock
8/19
08:30 am
ostx
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
High
Report
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
8/15
08:30 am
ostx
OS Therapies Reports Second Quarter 2024 Financial Results
High
Report
OS Therapies Reports Second Quarter 2024 Financial Results
8/9
09:00 am
ostx
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
High
Report
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
8/6
08:35 am
ostx
OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board
Low
Report
OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board
7/31
06:21 pm
ostx
OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”
High
Report
OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”